2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 18:37, 31 October 2023
, 31 October 2023→Clinical Trials
| Line 208: | Line 208: | ||
* significant improvement of six-minute walking test, blood biological age, and SF-36 scores | * significant improvement of six-minute walking test, blood biological age, and SF-36 scores | ||
* 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | * 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
|} | |} | ||